Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight-Loss drug liraglutide tested in kids as young as 6

NCT ID NCT07590219

Disease control Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug liraglutide, combined with healthy lifestyle changes, can help children aged 6 to 12 with severe obesity lose weight and improve heart function. Thirty children will receive either liraglutide injections plus lifestyle advice or lifestyle advice alone for 6 months. Researchers will measure changes in body mass index (BMI) and use advanced heart ultrasound to check for cardiovascular benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liraglutide (Saxenda)
What this could lead to
If it works, this could point toward a medication option to help severely obese children lose weight and improve heart health.
What could go wrong
This is a small, early-phase trial with only 30 children, so results may not apply broadly. Liraglutide can cause nausea, vomiting, and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 6-12 years * BMI Z-score ≥ +3 * Previous unsuccessful lifestyle intervention Exclusion Criteria: * Severe chronic diseases * Cardiac disease * Dermatological contraindication * Use of interfering medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular function are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

morbid obesity Pediatric Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular function Childhood obesity Echocardiography Liraglutide Severe obesity Speckle tracking

Contacts and locations

Locations

  • Childrens Institute - University of Sao Paulo

    São Paulo, São Paulo, 05403-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.